Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTY720 vs MMF in De Novo Renal Transplant
NCT00239785Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2003
- Primary completion
- Apr 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of fingolimod in kidney transplant rejection (3 arms), sponsored by Novartis. Primary endpoints: Incidence of Biopsy-Proven Acute Rejection, Graft Loss, Death, or Lost to Follow-up at 12 months, Biopsy-Proven Acute Rejection (BPAR) at 12 months and 2 more. Started Apr 2003; status: completed.
02
Drugs
fingolimod
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00239785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00239785.